Fluorouracil

Elevate-Derm conference insights, intralesional 5-fluorouracil benefits, psoriasis early detection, brevilin-A efficacy, eczema awareness, dermatology provider roles, vitiligo cardiovascular risk, plaque psoriasis treatments, topical CHE treatment launch, efinaconazole efficacy, roflumilast cream success, alitretinoin vs. phototherapy, acne treatment clearance, joint health prioritization, advanced skin treatment precision, bimekizumab-bkzx upgrades, ruxolitinib cream cases, treatment transparency, skin app accuracy, melanoma test power, eyelash growth scenarios, skin quality scale, PN health resource use, vitiligo zinc/copper levels, combined AD treatment, acne case pearls, eczema tools, dupilumab pediatric benefits, Zoryve approval, psoriasis in skin of color, chronic urticaria treatment success.

FDA approves zolbetuximab (Vyloy) as first-line treatment for HER2-negative, CLDN18.2-positive gastric/GEJ adenocarcinoma, following resubmission after CRL. Supported by phase 3 SPOTLIGHT and GLOW studies, zolbetuximab showed improved PFS in combination with mFOLFOX6 and CAPOX.

Advanced ICC patients typically face rapid disease progression and poor prognosis, with gemcitabine plus cisplatin being the primary chemotherapy regimen. HAIC + L + P treatment showed extended mOS and mPFS, higher ORR and DCR, and reduced intrahepatic tumor diameter compared to systemic chemotherapy. HAIC delivers high drug concentrations to liver lesions, reducing systemic toxicity. Targeted therapy and immunotherapy, such as lenvatinib and PD-1 inhibitors, offer additional benefits. Combination therapies, including HAIC with lenvatinib and PD-1 inhibitors, demonstrated improved tumor remission, increased OS and PFS, and fewer AEs. Further large-sample, randomized controlled trials are needed to validate these findings.

References discuss hepatocellular carcinoma epidemiology, chemoembolization, autophagy regulation, and fasting effects on cancer therapy.

MIT study finds 5-fluorouracil (5-FU) kills GI cancer cells by interfering with RNA synthesis, not DNA. Combining 5-FU with RNA-affecting drugs could be more effective than current DNA-damaging drug combinations.

New MIT study reveals 5-fluorouracil kills GI cancer cells by interfering with RNA synthesis, not DNA, challenging current treatment combinations. Researchers suggest combining 5-FU with RNA synthesis-affecting drugs for better efficacy and propose clinical trials with altered drug schedules.

Processa Pharmaceuticals has initiated a Phase II trial of Next Generation Capecitabine (NGC-Cap) for advanced or metastatic breast cancer, aiming to compare its safety and efficacy to FDA-approved capecitabine. The trial, involving 60-90 patients across 30 global sites, seeks optimal dosing under the FDA's Project Optimus Initiative and personalized therapy potential. NGC-Cap combines PCS6422, a DPD enzyme inhibitor, with low-dose capecitabine to enhance cancer-killing effects while reducing side effects.

Processa Pharmaceuticals initiates Phase 2 trial of NGC-Cap for metastatic breast cancer, comparing it to monotherapy capecitabine. The trial aims to evaluate NGC-Cap's safety-efficacy and determine optimal dosage regimens.

Bladder preservation using trimodality therapy (TMT) is now a viable alternative to radical cystectomy for muscle-invasive bladder cancer (MIBC), offering comparable outcomes. Recent trials and guidelines support TMT as a primary treatment option, challenging the historical gold standard of cystectomy. Ongoing research explores TMT's potential in non-muscle invasive and metastatic bladder cancer settings, with promising results suggesting its broader application.